Company

UCB SA

Headquarters: Brussels, Belgium

Employees: 8,600

CEO: Mr. Jean-Christophe Tellier

Euronext: UCB +1.43%

Market Cap

€15.47 Billion

EUR as of Jan. 1, 2024

US$17.08 Billion

history Market Cap History

UCB SA market capitalization over time

Evolution of UCB SA market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of UCB SA

Detailed Description

UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium.

Top 1-year algo backtest: +240.10%

$10,000 in February 2023 would now be $34,010 by following it 5 minutes per day at market close.

How much did you gain in the last 12 months?

Stocks & Indices

UCB SA has the following listings and related stock indices.


Stock: Euronext: UCB wb_incandescent

Stock: FSX: UNC wb_incandescent

Stock: FSX: UNC0 wb_incandescent

Stock: OTC: UCBJY wb_incandescent

Stock: OTC: UCBJF wb_incandescent

Details

Headquarters:

AllEe de la Recherche, 60

Brussels, 1070

Belgium

Phone: 32 2 559 99 99

Fax: 32 2 559 99 00